Durham, North Carolina 27710

  • Metastatic Cancer


RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase I/II trial to study the effectiveness of radiolabeled monoclonal antibody therapy in treating patients who have primary or metastatic brain cancer.

Study summary:

OBJECTIVES: - Determine the toxic effects of intracranial iodine I 131 labeled anti-tenascin monoclonal antibody 81C6 in patients with primary or metastatic anaplastic gliomas. - Determine the objective therapeutic response of these patients treated with this regimen. OUTLINE: This is a dose escalation study of iodine I 131 labeled anti-tenascin monoclonal antibody 81C6 (MOAB 81C6). Patients are stratified by prior external beam radiotherapy (yes vs no). Patients receive iodine I 131 labeled MOAB 81C6 intraventricularly followed by unlabeled MOAB 81C6 intraventricularly. Cohorts of 3-6 patients receive escalating doses of iodine I 131 labeled MOAB 81C6 until the maximum tolerated dose is determined. The MTD is defined as the highest dose preceding that at which 3 of 6 patients experience dose-limiting toxicity. Patients are followed monthly for 2 years, every 2 months for 2 years, and then every 3 months thereafter. PROJECTED ACCRUAL: A total of 3-6 patients per cohort will be accrued for this study.


DISEASE CHARACTERISTICS: - Histologically proven primary or metastatic malignant supratentorial anaplastic glioma - Newly diagnosed or recurrent - No diffusely infiltrating or multifocal tumor - No tumor with subependymal spread - Resection of glioma and placement of an intralesional catheter into the surgical cavity required before study - Measurable lesion on enhanced CT scan or MRI - No measurable enhancing lesion greater than 1.0 cm beyond cavity margin - Neoplastic cell reactivity with tenascin demonstrated by immunohistology with either a polyclonal rabbit antibody or a monoclonal murine antibody PATIENT CHARACTERISTICS: Age: - 3 and over Performance status: - Karnofsky 50-100% Hematopoietic: - Absolute neutrophil count greater than 1,000/mm^3 - Platelet count greater than 100,000/mm^3 Hepatic: - Bilirubin less than 1.5 mg/dL - AST less than 1.5 times normal - Alkaline phosphatase less than 1.5 times normal Renal: - Creatinine less than 1.2 mg/dL Other: - Not pregnant - Negative pregnancy test - Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy: - Not specified Chemotherapy: - At least 6 weeks since prior chemotherapy unless unequivocal evidence of tumor progression Endocrine therapy: - Corticosteroids allowed if at lowest possible dose and dose stable for at least 10 days prior to entry Radiotherapy: - At least 3 months since prior radiotherapy to site of measurable disease unless unequivocal evidence of tumor progression Surgery: - See Disease Characteristics



Primary Contact:

Study Chair
Darell D. Bigner, MD, PhD
Duke Cancer Institute

Backup Contact:


Location Contact:

Durham, North Carolina 27710
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: March 30, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.